ReviewEndocrine2013
Should we abandon statins in the prevention of bone fractures?
Review in Endocrine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 5 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Nitrogen-containing bisphosphonate for vascular calcification: animal experiments, systematic review and meta-analysis.BMC cardiovascular disorders · 2025Pooled it
- PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis.BMC musculoskeletal disorders · 2024Pooled it
- Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and the Risk of Fracture: A Systematic Review and Meta-analysis of Randomized Controlled Trials.Calcified tissue international · 2023Pooled it
- Bisphosphonates, atherosclerosis and vascular calcification: update and systematic review of clinical studies.Clinical interventions in aging · 2017Pooled it
- Effects of Statins on Bone Mineral Density and Fracture Risk: A PRISMA-compliant Systematic Review and Meta-Analysis.Medicine · 2016Pooled it
- The association of lipids and novel non-statin lipid-lowering drug target with osteoporosis: evidence from genetic correlations and Mendelian randomization.BMC musculoskeletal disorders · 2025Article
- Comparative efficacy and safety of statins for osteoporosis: a study protocol for a systematic review and network meta-analysis.BMJ open · 2022Article
- Metabolic factors and hip fracture risk in a large Austrian cohort study.Bone reports · 2020Article
- Bone-targeted delivery of simvastatin-loaded PEG-PLGA micelles conjugated with tetracycline for osteoporosis treatment.Drug delivery and translational research · 2018Article
- Comparative impact of systemic delivery of atorvastatin, simvastatin, and lovastatin on bone mineral density of the ovariectomized rats.Endocrine · 2018Article
- Atorvastatin-loaded micelles with bone-targeted ligand for the treatment of osteoporosis.Drug delivery · 2017Article
- Women's Expectations for Breast Cancer Prevention and Early Detection: High Expectations Can Be Achieved.The oncologist · 2016Article
- Lansoprazole Upregulates Polyubiquitination of the TNF Receptor-Associated Factor 6 and Facilitates Runx2-mediated Osteoblastogenesis.EBioMedicine · 2015Article
- Lipid metabolism disorders and bone dysfunction--interrelated and mutually regulated (review).Molecular medicine reports · 2015Review
- Increased low-density lipoprotein cholesterol level is associated with non-vertebral fractures in postmenopausal women.Endocrine · 2015Article
- Pharmacovigilance in Italy: An overview.Journal of pharmacology & pharmacotherapeutics · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis increases dramatically with age. About 40 % of women in developed countries will experience an osteoporosis-related fracture in the course of their lifetime, with men experiencing approximately one-third to one-half the risk of women. The "lipid hypothesis of osteoporosis" claims for a role of oxidized lipids as a contributing factor in osteoporosis. On the other hand, statins are supposed to exert anabolic effects on the bone, either through their lipid-lowering action or signal pathways that are independent of their effects on lipid levels. The epidemiological evidence seems to suggest that higher triglycerides may give some protection against fracture, although no association with reduced fracture risk has been reported between lipid-lowering drug (except statins) users and non-users. The epidemiological evidence for a role of statins in osteoporosis is strong, with a lower fracture risk ranging from 30 to 40 % in statin users versus non-users. However, some pitfalls inherent to observational studies (high heterogeneity, residual confounding, potential publication bias) and the lack of association in randomized trials suggest caution. At the moment, the evidence for a role of statins in prevention of osteoporosis is insufficient to recommend starting statin therapy with the aim to prevent osteoporosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.